<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23880543</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1080-6059</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>8</Issue><PubDate><Year>2013</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Emerging infectious diseases</Title><ISOAbbreviation>Emerg Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Fatal case of enterovirus 71 infection and rituximab therapy, france, 2012.</ArticleTitle><Pagination><StartPage>1345</StartPage><EndPage>1347</EndPage><MedlinePgn>1345-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3201/eid1908.130202</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kassab</LastName><ForeName>Somar</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Saghi</LastName><ForeName>Tahar</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Boyer</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lafon</LastName><ForeName>Marie-Edith</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Gruson</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lina</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fleury</LastName><ForeName>Herv&#xe9;</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schuffenecker</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Infect Dis</MedlineTA><NlmUniqueID>9508155</NlmUniqueID><ISSNLinking>1080-6040</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058846">Antibodies, Monoclonal, Murine-Derived</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058846" MajorTopicYN="N">Antibodies, Monoclonal, Murine-Derived</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018792" MajorTopicYN="N">Encephalitis, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008224" MajorTopicYN="N">Lymphoma, Follicular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060046" MajorTopicYN="N">Maintenance Chemotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV-71</Keyword><Keyword MajorTopicYN="N">France</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">fatal case</Keyword><Keyword MajorTopicYN="N">rhomboencephalitis</Keyword><Keyword MajorTopicYN="N">rituximab</Keyword><Keyword MajorTopicYN="N">viruses</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23880543</ArticleId><ArticleId IdType="pmc">PMC3739532</ArticleId><ArticleId IdType="doi">10.3201/eid1908.130202</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778&#x2013;90 and. 10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr Opin Virol. 2012;2:199&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482716</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuffenecker I, Mirand A, Antona D, Henquell C, Chomel JJ, Archimbaud C, et al. Epidemiology of human enterovirus 71 infections in France, 2000&#x2013;2009. J Clin Virol. 2011;50:50&#x2013;6. 10.1016/j.jcv.2010.09.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2010.09.019</ArticleId><ArticleId IdType="pubmed">21035387</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallet S, Legrand Quillien MC, Dailland T, Podeur G, Gouriou S, Schuffenecker I, et al. Fatal case of enterovirus 71 infection, France, 2007. Emerg Infect Dis. 2009;15:1837&#x2013;40. 10.3201/eid1511.090493</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1511.090493</ArticleId><ArticleId IdType="pmc">PMC2857235</ArticleId><ArticleId IdType="pubmed">19891879</ArticleId></ArticleIdList></Reference><Reference><Citation>Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187&#x2013;98 and. 10.1053/j.seminhematol.2010.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminhematol.2010.01.002</ArticleId><ArticleId IdType="pubmed">20350666</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartier P, Tournilhac O, Archimbaud C, Lazaro L, Chaleteix C, Millet P, et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis. 2003;36:e47&#x2013;9 and. 10.1086/345746</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/345746</ArticleId><ArticleId IdType="pubmed">12539090</ArticleId></ArticleIdList></Reference><Reference><Citation>Servais S, Caers J, Warling O, Frusch N, Baron F, De Prijck B, et al. Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma. Br J Haematol. 2010;150:379&#x2013;81 and. 10.1111/j.1365-2141.2010.08202.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2010.08202.x</ArticleId><ArticleId IdType="pubmed">20408837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R, Buckland M, Davies L, Halmagyi GM, Rogers SL, Oberste S, et al. Enterovirus 71 meningoencephalitis complicating rituximab therapy. J Neurol Sci. 2011;305:149&#x2013;51 and. 10.1016/j.jns.2011.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2011.03.009</ArticleId><ArticleId IdType="pubmed">21444094</ArticleId></ArticleIdList></Reference><Reference><Citation>Misbah SA, Spickett PC, Ryba PCJ, Hockaday JM, Kroll JS, Sherwood C, et al. Chronic enteroviral meningoencephalitis in agammaglobulinemia: casereport and literature review. J Clin Immunol. 1992;12:266&#x2013;70 and. 10.1007/BF00918150</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00918150</ArticleId><ArticleId IdType="pubmed">1512300</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299&#x2013;306 and. 10.1016/j.micinf.2007.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>